The Endpoints Slack interview: Cellino CEO Nabiha Saklayen on cell therapy's future, Elon Musk and time travel
Nabiha Saklayen founded Cellino Biotech just as she was finishing her PhD in physics at Harvard in 2017, while she was still in her 20s.
The startup is trying to create automated ways to produce cell therapies and raised an $80 million Series A round in 2022 to get to work. Endpoints News caught up with Saklayen on how that effort is going, as well as her thoughts on Elon Musk, mission control at Cellino, and even time travel.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.